细胞对抗血小板因子4疾病的病原发生的贡献
Jared Treverton1,2,3, Mark Lychacz2,3, Donald M Arnold2,3
1Department of Biochemistry and Biomedical Sciences.
Current opinion in hematology
|November 4, 2025
概括
除了血小板之外的免疫细胞,如中性粒细胞和单细胞,在抗血小板因子4 (PF4) 疾病中驱动血栓形成. 了解这些细胞相互作用揭示了氨酸诱导的血小板缩 (HIT) 和疫苗诱导的免疫血小板缩和血栓形成 (VITT) 的新治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 血栓形成研究研究
背景情况:
- 抗血小板因子4 (PF4) 疾病,包括氨酸诱导的血小板缺血症 (HIT) 和疫苗诱导的免疫血小板缺血症和血栓症 (VITT),是抗体介导的疾病,导致血小板和血栓的低水平.
- 新出现的疾病,如类似VITT的血栓显著性单克隆性胃病变 (MGTS),具有相似的机制.
- 临床表现的变化需要更深入地了解潜在的细胞和分子通路.
研究的目的:
- 审查最近关于抗PF4疾病细胞和分子机制的发现.
- 阐明免疫和血管细胞在血栓形成和临床结果中的作用.
- 在不同抗PF4疾病中确定统一机制和新的治疗点.
主要方法:
- 关于抗PF4疾病的最新科学文献的综述.
- 对参与血栓形成的细胞和分子通路的分析.
- 检查中性粒细胞,单细胞和内皮细胞的作用.
主要成果:
- 血小板不是唯一的驱动因素;免疫和血管细胞极大地影响了血栓形成的严重程度.
- 中性粒细胞通过NETosis贡献,单细胞释放富含组织因子的微粒,内皮细胞促进血栓炎症.
- 病变发生过程涉及多种细胞类型之间的复杂相互作用,从而产生原血栓状态.
结论:
- 在抗PF4疾病中,与血小板一起,先天性免疫细胞起着重要作用.
- 了解细胞间通路解释了可变的临床结果,并提出了新的治疗点.
- 这些知识有助于改善对HIT,VITT和相关疾病的诊断和治疗策略.
相关概念视频
01:18Structure and Function of Platelets
2.9K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.9K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
01:22Formation of the Platelet Plug
8.6K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.6K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
11.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.9K
01:16Clot Retraction and Fibrinolysis
8.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.3K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K